TrialStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2022

[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials].

Etienne Mathier et al.PubMed ↗Publisher ↗

No numbers read from the abstract.